PA
RARE icon

Parallel Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parallel Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57K Buy
1,708
+83
+5% +$2.06K ﹤0.01% 2056
2026
Q1 		$34K Buy
1,625
+1,440
+778% +$32.4K ﹤0.01% 2216
2025
Q4 		$4.25K Buy
185
+31
+20% +$1.02K ﹤0.01% 2900
2025
Q3 		$4.63K Sell
154
-578
-79% -$17.3K ﹤0.01% 2809
2025
Q2 		$26.6K Buy
732
+669
+1,062% +$24.1K ﹤0.01% 2059
2025
Q1 		$2.28K Sell
63
-162
-72% -$6.74K ﹤0.01% 2939
2024
Q4 		$9.47K Sell
225
-294
-57% -$14.6K ﹤0.01% 2425
2024
Q3 		$28.8K Buy
519
+308
+146% +$15.7K ﹤0.01% 1883
2024
Q2 		$8.67K Buy
211
+143
+210% +$6.11K ﹤0.01% 2364
2024
Q1 		$3.17K Buy
68
+37
+119% +$1.75K ﹤0.01% 2671
2023
Q4 		$1.48K Sell
31
-238
-88% -$9.23K ﹤0.01% 2867
2023
Q3 		$9.59K Sell
269
-175
-39% -$6.93K ﹤0.01% 2227
2023
Q2 		$20.5K Buy
444
+303
+215% +$14.1K ﹤0.01% 1838
2023
Q1 		$5.65K Sell
141
-194
-58% -$8.32K ﹤0.01% 2365
2022
Q4 		$15.5K Buy
335
+221
+194% +$8.69K ﹤0.01% 1829
2022
Q3 		$5K Buy
114
+17
+18% +$874 ﹤0.01% 2313
2022
Q2 		$6K Buy
97
+42
+76% +$2.58K ﹤0.01% 2203
2022
Q1 		$4K Sell
55
-34
-38% -$2.37K ﹤0.01% 2398
2021
Q4 		$7K Buy
89
+84
+1,680% +$6.83K ﹤0.01% 2270
2021
Q3 		$0 Buy
+5
New +$452 ﹤0.01% 3234
2021
Q2 		– Sell
-7
Closed -$1K – 3038
2021
Q1 		$1K Buy
+7
New +$953 ﹤0.01% 2676
2019
Q3 		– Sell
-28
Closed -$2K – 2473
2019
Q2 		$2K Hold
28
– – ﹤0.01% 2114
2019
Q1 		$2K Sell
28
-270
-91% -$15.4K ﹤0.01% 2098
2018
Q4 		$12K Buy
298
+252
+548% +$13.8K ﹤0.01% 1254
2018
Q3 		$4K Hold
46
– – ﹤0.01% 1818
2018
Q2 		$3K Hold
46
– – ﹤0.01% 1761
2018
Q1 		$2K Hold
46
– – ﹤0.01% 1868
2017
Q4 		$2K Buy
+46
New +$2.25K ﹤0.01% 1873

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parallel Advisors's RARE Position: Q2 2026 in Review

Parallel Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 5.1% in Q2 2026, buying an estimated $2.06K and bringing the position to 1,708 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

Parallel Advisors first reported a position in RARE in Q4 2017 and has held it in 28 quarters since. 99 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Parallel Advisors held 1,708 shares of Ultragenyx Pharmaceutical worth $57K as of Q2 2026.
  • Parallel Advisors bought 83 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.06K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2056 holding.
  • Parallel Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 28 quarters since.
  • 99 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.